Vilon
Also known as: Lys-Glu, Lysylglutamate, KE dipeptide
Overview
Vilon is a synthetic dipeptide (Lys-Glu) bioregulator developed by Professor Vladimir Khavinson from amino acid analysis of Thymalin, a natural thymus extract with immunomodulatory properties. It is one of the simplest bioactive peptides known, yet demonstrates measurable effects on immune cell proliferation, gene expression via chromatin remodeling, potential lifespan extension in animal models, and anti-inflammatory cytokine regulation. Its mechanism involves selective deheterochromatinization — epigenetic activation of silenced gene regions in aging cells.
Mechanism of Action
Vilon causes progressive activation (deheterochromatinization) of facultative heterochromatin in aging cells, selectively reactivating silenced genes by loosening chromatin structure without disturbing structural heterochromatin. It interacts with the CHUK gene encoding a component of the NF-κB signaling pathway, modulating cytokine production and immune cell activation at a fundamental regulatory level. Specifically, it stimulates T-cell precursor (thymocyte) proliferation and maturation, increases CD4 and CD5 expression on thymic cells, increases argyrophilic protein expression in cell nuclei, and reduces inflammatory cytokine synthesis by up to 6-fold.
Potential Benefits
- T-cell maturation and proliferation support
- CD4+ and CD5+ expression enhancement
- Up to 6-fold reduction in inflammatory cytokine synthesis
- Epigenetic activation of silenced gene regions in aging cells
- Thymic recovery after gamma radiation in animal models
- NF-κB pathway modulation balancing immune activation and inflammation
- Potential type 1 diabetes autoimmune modulation
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | 100 mcg daily for 10 days |
| Intermediate | 150 mcg daily for 15 days |
| Advanced | 200 mcg daily for 20 days, repeat every 6 months |
| Cycle Duration | 10-20 days |
Khavinson dipeptide (Lys-Glu). Immune system bioregulator.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous Injection High
Standard Russian bioregulator route.
Oral (sublingual) Lower but practical
Short dipeptide retains some oral activity.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Vilon:
Immune Bioregulator Stack
Khavinson immune-longevity protocol for age-related immune decline.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Refrigerate at 2-8°C after reconstitution. Do not freeze reconstituted solution. |
|---|
Typical vial sizes: 2-5 mg. Add bac water slowly down the side of the vial, swirl gently — do not shake. Use insulin syringe for precise dosing.
Need exact syringe measurements?
Amino Acid Sequence
Lys-Glu (KE)
Side Effects & Safety
- Well-tolerated in available studies
- Minimal adverse effects reported
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Pharmacokinetics
| Half-Life | Not well characterized for this peptide; consult primary literature |
|---|---|
| Storage | Store lyophilized peptide at -20°C (long-term) or 2-8°C (short-term, under 30 days). Reconstituted: refrigerate at 2-8°C and use within 28-30 days. Protect from light. Do not freeze reconstituted solution. |
Synergistic Compounds
The following compounds have been studied alongside Vilon for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA Staff Reviewers Say ‘No’ to 7 Compounded Peptides Ahead of July PCAC Vote
FDA staff reviewers urged against adding seven popular peptides to the 503A bulks list ahead of the July PCAC meeting, citing weak human data and safety uncertainty.
FDA reviewers urge ‘no’ on BPC-157, TB-500, MOTS-c ahead of July 2026 compounding vote
FDA reviewers’ June 29 briefings recommend against listing seven popular peptides for 503A compounding, citing limited human data and immunogenicity risk.
Medicare Starts Paying for Obesity Drugs Today — Bridge Program Opens $50 Access for Millions
Medicare's new $50 Bridge program covering Wegovy, Zepbound, Foundayo, and oral Wegovy for obesity launched July 1 — the first Medicare weight-loss benefit.
FDA staff urges caution on compounded peptides ahead of July advisory meeting
Ahead of the July 23–24 Pharmacy Compounding Advisory Committee meeting, FDA staff briefings recommend against listing seven popular peptides for compounding.